Log In
Print
BCIQ
Print
Print this Print this
 

Emselex, Enablex, darifenacin

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionMuscarinic acetylcholine receptor M3 antagonist
Molecular Target Muscarinic acetylcholine receptor M3 (CHRM3) (HM3)
Mechanism of ActionMuscarinic acetylcholine receptor M3 antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationIncontinence
Indication DetailsTreat overactive bladder (OAB)
Regulatory Designation

Partner

Actavis plc; Merus Labs International Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today